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Abstract 
Background: Ovarian cancer is the most lethal gynecological malignancy due to its frequent recurrence and drug 
resistance even after successful initial treatment. Accumulating scientific evidence indicates that subpopulations 
of cancer cells with stem cell-like properties, such as so-called side population (SP) cells, are primarily responsible 
for these recurrences. A better understanding of SP cells may provide new clues for detecting and targeting these 
cancer-initiating cells and ultimately help to eradicate cancer. Changes in glycosylation patterns are remarkable 
features of SP cells. Here, we isolated SP cells from ovarian cancer cell lines and analyzed their glycosylation patterns 
using multiple glycomic strategies.
Methods: Six high-grade serous ovarian cancer cell lines were used for SP cell isolation. Among them, HO8910 pm, 
which contained the highest proportion of SP cells, was used for glycomic analysis of SP cells. Cell lysate of SP cells 
and main population cells was applied to lectin microarray and mass spectrometry for glycan profiling. Differently 
expressed glycan structures were further verified by lectin blot, flow cytometry, and real-time PCR analysis of their 
relevant enzymes.
Results: Expression of core fucosylated N-glycan and tumor-associated Tn, T and sT antigens were increased in SP 
cells. By contrast, SP cells exhibited decreased hybrid glycan, α2,3-linked sialic glycan and multivalent sialyl-glycan.
Conclusions: Glycan structures, such as Tn, T, sT antigens, and core fucosylation may serve as biomarkers of ovarian 
cancer stem cells.
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Background
Ovarian cancer is one of the most lethal gynecologi-
cal malignancies [1]. The high mortality rate of ovarian 
cancer has been attributed both to late diagnosis due to 
lack of early symptoms and to recurrence accompanied 
by drug resistance [2–4]. Although 80  % of patients are 
initially responsive to optimal cytoreductive surgery plus 
platinum-based chemotherapy, recurrent cancer is inevi-
table in vast majority of cases. Along with recurrence, 
drug resistance develops, leading to death in 70 % of ovar-
ian cancer patients [5]. Thus, recurrence and drug resist-
ance are main challenges in ovarian cancer treatment.
Accumulating scientific evidence suggests that tumors 
are driven by relatively rare and biologically distinct can-
cer-initiating cells, so-called cancer stem cells (CSCs), 
which are capable of self-renewal and further differen-
tiation [6–8]. These cells are resistant to regular chemo-
therapy because they remain quiescent for a long time, 
proliferate slowly and excrete drugs easily [7, 8]. Detect-
ing and eliminating CSCs would prohibit relapse and 
improve survival of ovarian cancer patients [9].
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Glycosylation is the most prevalent post-transla-
tional modification involved in many physiological 
and pathological processes. A large number of studies 
have demonstrated that glycans participate in cancer 
initiation [10], development [11–14], and drug resist-
ance [15]. In addition, several reports have suggested 
that glycans and glycosyltransferases play impor-
tant roles in CSC function. For example, increased 
fucosylation promotes invasive and metastatic prop-
erties of head and neck cancer stem cells [16]. β1,4-
N-Acetylgalactosaminyltransferase (GalNAcT) III 
modulates the stemness of colon cancer via EGFR sign-
aling pathway [17]. Glycans can also serve as potential 
CSC biomarkers. In combination with traditional bio-
markers, glycans can be used to isolate more malignant 
CSCs. For example, anti-CD133 antibody, together with 
SSA (Sambucus sieboldiana) lectin, can identify CSCs 
of higher tumourigenicity in hepatocellular carcinoma 
[18]. Moreover, expression pattern of certain glycans 
on CSCs is distinct from that on normal stem cells, thus 
may improve the specificity of detecting and targeting 
CSCs [19]. Consequently, glycan biomarkers have more 
advantages with fewer side effects to harm the normal 
stem cells than general CSC markers. Glycomic analy-
sis may provide comprehensive glycome profiles and 
potential biomarkers of CSCs. The specific glycans of 
CSCs have potential clinical value as targets in patients 
undergoing chemotherapy.
So far, little is known about glycosylation of ovarian 
CSCs. In this study, an integrated strategy using lec-
tin array and mass spectrometry (MS) was employed to 
obtain the global glyco-information of ovarian cancer 
side population (SP) cells. Core fucosylated N-glycan and 
tumor-associated Tn, T and sT antigens were increased, 
while hybrid glycan, α2,3-linked sialic glycan and mul-
tivalent sialyl-glycan were decreased in SP cells. These 
differentially expressed glycans may serve as potential 
biomarkers of ovarian cancer SP cells.
Methods
Cell culture
The human high-grade serous ovarian cancer cell lines 
SKOV3 and HO8910 and their highly metastatic sub-
lines SKOV3 ip and HO8910 pm were purchased from 
the cell bank of Shanghai Institute of Biochemistry and 
Cell Biology (China). The high-grade ovarian cancer cell 
line A2780 and its cisplatin-resistant subline A2780-cp 
were obtained from Obstetrics and Gynecology Hos-
pital of Fudan University (China). All cell lines were 
routinely cultured in DMEM (Gibco Life Technologies, 
Carlsbad, CA, USA) supplemented with 10  % foetal 
bovine serum (Gibco) and 100 U/ml penicillin/strepto-
mycin (Gibco).
Side population sorting
SP sorting was performed as previously described [20]. 
Briefly, the fluorescent dye Hoechst 33342 (Sigma-
Aldrich, St. Louis, MO, USA) was added to a cell suspen-
sion (1 ×  106 cells/ml) at a final concentration of 5  μg/
ml. After incubation at 37  °C for 90  min, the cells were 
treated with 2 μg/ml propidium iodide (PI) and sorted on 
a MoFlo XDP cytometer (Beckman Coulter, Brea, CA, 
USA). Cells treated with verapamil before Hoechst 33342 
staining were used as negative control. Main population 
cells at the G0 stage were collected.
Spheroid formation assay
SP cells or MP cells were seeded at 2000 per well in 
24-well Ultra Low plates (Corning, New York, NY, USA) 
in DMEM/F12 medium (Gibco) containing 20  ng/ml 
fibroblast growth factor, 20 ng/ml epidermal growth fac-
tor, 2  % B27, insulin (R&D Systems, Minneapolis, MN, 
USA) and 2 mg/ml heparin (Sigma-Aldrich) and cultured 
for 21 days.
Cell cycle analysis
After cell sorting, 5 × 105 SP cells and MP cells were sus-
pended in phosphate-buffered saline (PBS) buffer con-
taining 50  μg/ml PI dividedly, incubated in the dark for 
30 min at room temperature, and analyzed with a CyAn 
ADP flow cytometer (Beckman Coulter). Data were ana-
lyzed with ModFit LT for Windows version 3.1.
Lectin microarray
After sorting, SP cells and MP cells were washed several 
times with PBS and frozen at −80 °C. For lectin microar-
ray analysis, 1 ×  105 cells were resuspended in 1  ml of 
PBS-T (containing 1 % TritonX-100), followed by sonica-
tion for 15 min and centrifugation at 14,000g for 15 min. 
The supernatant was recovered. Proteins were quan-
titated using a micro BCA kit (Thermo Scientific) and 
labelled with fluorescent dye Cy3 (Thermo Scientific). 
Samples with protein concentration of 250  ng/ml were 
applied to a LecChip (Glyco Technica) and incubated at 
20 °C for 16 h. The chip was then scanned with a GlycoS-
tation Reader 1200 (Glyco Technica) confocal scanner. 
Each lectin in LecChip has three replicates. To be nor-
malized, intensity of each well in lectin microarray was 
divided by the mean of total 135 wells’ intensity of the 
chip. We repeated lectin microarray analysis of SP and 
MP cells using independent samples to overcome bio-
logical bias.
Cell lysis preparation for mass spectrometry analysis
SP cells were rinsed with PBS. After washing, 2  % SDS 
containing protease inhibitor cocktail (Roche Diagnos-
tics, Roche Applied Science, Meylan, France) was used to 
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lyse the cells at 100  °C for 15  min. The lysate was then 
centrifuged at 14,000g for 30  min, and the supernatant 
was collected. The protein concentration in the superna-
tant was quantitated using a BCA kit (Thermo Scientific, 
San Jose, CA, USA).
N‑Glycan release and purification
For each cell line, 400 μg of protein in 200 μl of 2 % SDS 
was added to 200 μl of 8 M urea (Sigma-Aldrich) contain-
ing dithiothreitol (Sigma-Aldrich) to achieve a final con-
centration of 10 mM. After heating at 56 °C for 20 min, 
the samples were incubated in 40 mM ammonium bicar-
bonate (Sigma-Aldrich) containing 25  mM iodoaceta-
mide (Sigma-Aldrich) for 30 min at 37 °C in the dark. The 
sample was transferred to an ultrafiltration unit (Amicon 
Ultra-0.5, Ultracel-10 membrane; Millipore, Billerica, 
MA) and centrifuged at 14,000g for 15  min. A volume 
of 200 μl of 40 mM NH4HCO3 was added to the ultrafil-
tration unit and centrifuged to wash the sample. There-
after, 2  μl of PNGase F (New England BioLab, Ipswich, 
MA) in 200  μl of 40  mM NH4HCO3 was added to the 
device and incubated with shaking for 24 h at 37 °C. The 
ultrafiltration unit was transferred to a new collection 
tube and centrifuged at 14,000g for 15 min, and the filter 
membrane was washed with 200 μl of 40 mM NH4HCO3 
for three times. The solution in the collection tube was 
recovered and lyophilizedin a vacuum freeze dryer (Mar-
tin Christ GmbH, Osterode, Germany). To remove sialic 
acids, each sample was reconstituted in 50  mM ammo-
nium acetate buffer (pH  5.5) followed by desialylation 
with neuraminidase (15  mU) from V. cholerae (Roche) 
(Sigma-Aldrich, St. Louis, MO) at 37 °C overnight. Sub-
sequently, all samples were dried in a SpeedVac and 
redissolved in 50 μl of water (with 0.1 % TFA).
The N-glycans in solution were purified and desalted 
using a Porous Graphic Carbon Solid-Phase Extraction 
(PGC-SPE) as previously described [21]. The PGC-SPE 
microcolumn was a GELoader tip filled with porous 
graphic carbon powder. The microcolumn was prepared 
with 6 volumes of 0.1 % (v/v) trifluoroacetic acid (TFA) in 
80 % acetonitrile (ACN)/H2O (v/v) and equilibrated with 
water. The N-glycan solution was passed through the 
microcolumn 5 times to ensure complete adsorption. The 
N-glycans were eluted with 400 μl of 0.05 % (v/v) TFA in 
25 % (v/v) ACN and lyophilized.
Mass spectrometry analysis
N-Glycans were characterized by AXIMA Resonance 
MALDI QIT TOF MS (Shimadzu Corp, Kyoto, Japan). 
The lyophilized desialylated glycans were resuspended 
in 20  μl of water. Each sample (1  μl) was spotted on 
a MALDI target and dried in air at room tempera-
ture. To recrystallize the glycans, 1  μl of 12.5  mg/ml 
2,5-dihydroxybenzoic acid matrix (DHB, Sigma-Aldrich, 
Germany) dissolved in 50 % ACN containing 0.1 % TFA 
was added to the sample target. Each sample was spot-
ted in five replicates. Glycan structures were analyzed 
using Glyco Workbench (http://code.google.com/p/
glycoworkbench/).
Launchpad software (Shimadzu Biotech, Kyoto, Japan) 
was used to acquire and process the MALDI MS data. 
The relative peak intensities were calculated as previously 
described [22, 23], that relative intensity of each type of 
N-glycan was calculated by dividing the intensity of a 
given type of N-glycan by sum of the total 25 N-glycans 
intensity. Relative standard deviation (RSD) percentages 
based on relative intensity values were used to estimate 
the stability of mass spectrometry. Relative intensity of 
the five replicates of a certain N-glycan were averaged 
and compared between SP and MP cells. p  <  0.05 were 
considered statistically significant. SP/MP ratios were 
calculated to express magnitude of changes. Cut-off of 
significant changes was set as >1.5 or <0.67 folds.
Lectin blot
The proteins isolated from SP cells and MP cells were 
analyzed by SDS-PAGE and lectin blot. In brief, sam-
ples were mixed with 5× loading buffer, boiled and 
separated by 10  % SDS–polyacrylamide gel electropho-
resis. The proteins in the gels were transferred to PVDF 
membranes (Millipore, Bedford, MA, USA). The PVDF 
membranes were blocked with TBST (150  mM NaCl, 
10 mM Tris–HCl, 0.05 % v/v Tween 20, pH 7.5) contain-
ing 5 % bovine serum albumin for 1 h at room tempera-
ture and incubated with biotinylated Agaricus bisporus 
(ABA; Vector Laboratories, Burlingame, CA) or Vicia 
villosa lectin (VVA; Vector Laboratories) for 2 h at room 
temperature. After washing with TBST for 3 times, the 
membranes were incubated with horseradish peroxidase 
streptavidin (Vector Laboratories) for 30  min at room 
temperature. Signals were subsequently detected using 
an ECL assay kit.
Total RNA extraction and quantitative real‑time PCR 
analysis
Total RNA was extracted with TRIzol™ reagent (Invitro-
gen, Carlsbad, CA, USA), and 2 μg of RNA was used to 
synthesize cDNA using an RT Master Mix kit (Takara, 
Shiga, Japan). Real-time PCR analysis was performed 
using an ABI 7500 Fast Real-time PCR system (Applied 
Biosystems, Switzerland) for 40 cycles (15  s at 95  °C, 
30 s at 60  °C). A 2-μl aliquot of cDNA was amplified in 
20  μl system using the SYBR-green Premix Real-time 
PCR kit (Takara) system according to the manufactur-
er’s instruction. The primer sequences were as follows: 
GAPDH, GTCAAGGCTGAGAACGGGAA (forward) 
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and AAATGAGCCCCAGCCTTCTC (reverse); Oct4, 
GACAACAATGAAAATCTTCAGGAGA (forward) and 
TTCTGGCGCCGGTTACAGAACCA (reverse); Nanog, 
CAAAGGCAAACAACCCACTT (forward) and TCTGC 
TGGAGGCTGAGGTAT (reverse); Fut8, TCTTCATCCC 
CGTCCTCCA (forward) and GAGACACCCACCACA 
CTGCA (reverse); C1galt1, CATCCCTTTGTGCCAGAA 
CACC (forward) and GCAAGATCAGAGCAGCAACC 
AG (reverse); St3gal1, GGGCAGACAGCAAAGGGAA 
(forward) and GGCCGTCACGTTAGACTCAAA (reverse).
Flow cytometry
After sorting, the SP cells and MP cells were cultured for 
5  weeks in the previously mentioned medium in 6-well 
Ultra Low plates (Corning). The spheres were divided 
into single cells, stained with fluorescent-labelled ABA 
and VVA (Vector Laboratories) for 15  min at room 
temperature, and detected using CyAn ADP (Beckman 
Coulter).
Statistical analyses
Means of continuous data were compared using Student’s 
t test by SPSS software (version 16.0), p < 0.05 was con-
sidered statistically significant. The results shown in fig-
ures were expressed as mean ± SD.
Results
Ovarian cancer SP cells exhibit stem cell‑like properties
To enrich SP cells, we analyzed six serous ovarian can-
cer cell lines, including SKOV3, HO8910 and their highly 
metastatic derivatives SKOV3 ip and HO8910  pm, as 
well as A2780 and its drug-resistant derivative A2780 cp. 
HO8910  pm cells exhibited 4.63  % Hoechst low stain-
ing SP cells, as previously reported [20] (Fig. 1a). Other 
cell lines exhibited only small amounts of SP cells, which 
were inadequate for glycoprofiling. Thus, we chose 
HO8910 pm cells for further studies.
Compared with the main population (MP) cells, SP 
cells exhibited higher self-renewal capacity. After plating 
in ultra-low attachment plates for 3  weeks, the SP cells 
formed significantly larger numbers of spheroids than 
MP cells. Moreover, the spheroids of SP cells were much 
larger in size (Fig. 1b, c). To further characterize the stem 
cell-like features of SP cells, we analyzed the expres-
sion of stem genes using real-time PCR. Both Oct-4 and 
Nanog were over-expressed in SP cells (Fig. 1d). CSCs are 
considered to reside in a stable quiescent state in the G0 
state of the cell cycle and are therefore resistant to chem-
otherapies [7]. We also examined the cell cycle of SP cells: 
nearly 97.5 % were arrested in the G0/G1 state (Fig. 1e), 
whereas only 66.17 % of unsorted HO8910 pm cells were 
in the G1 state.
Lectin array analysis of SP cells and MP cells
To obtain more comprehensive information about the 
global glycosylation of SP cells, lectin array including 45 
lectins were analyzed. Signal intensity of 9 lectins were 
significantly different between SP and MP cells in both of 
the two experiments (Fig. 2; Table 1).
Among O-glycan binding lectins, signal intensity of 
ABA, PNA, VVA, SBA, GSL-IA4, and GSL-IB4 were 
higher in SP cells, indicating a higher expression of Tn 
(GalNAc-α-Ser/Thr), T (Galβ1-3 GalNAc-α-Ser/Thr), 
and sT (sialyl-T) antigens in these cells. Among these lec-
tins, intensities of ABA, VVA, which recognize T, sT and 
Tn antigens, were the highest in two experiments, respec-
tively. ABA, PNA, VVA, GSL-IB4differed significantly 
in the two experiments. In contrast, SP cells exhibited 
a significantly lower intensities for (Gal β1-4GlcNAc)n 
(poly LacNAc) (LEL) and multivalent sialyl glycan bind-
ers (WGA).
Among N-glycans, SP cells showed significantly 
stronger intensity of fucosylation binder AAL, which 
recognizes the core fucose (Fuc) and Lewis X structure. 
A higher intensity for AOL, which recognizes both core 
Fuc and Fuc α1-2 (galactoside β1-4) n-acetylglucosamine 
(Fuc α1-2(Gal β1-4) GlcNAc), was also observed in SP 
cells. However, SP cells exhibited relatively weak intensity 
to UEA-I, which recognizes Fuc α1-2(Gal β1-4) GlcNAc. 
These results together indicated that core fucosylation 
glycans were increased in SP cells. In addition, the signal 
for α2-3 linked sialic acids (Sia) binders (MAL) was sig-
nificantly decreased in SP cells.
MS analysis of the N‑glycan profiles of SP cells and MP cells
To obtain more detailed information about the N-glycan 
structures and their relative intensities, we compared 
N-glycan profile of the whole proteome of SP cells and 
MP cells using MS. Twenty-five N-glycans were detected 
of both cell populations, and were shown in Fig. 3. Sta-
tistical analysis was conducted to determine the quan-
titative differences in glycans between SP and MP cells. 
A comparison based on different classes (high mannose, 
hybrid, and complex) were shown in Fig. 4. The relative 
intensities of each corresponding structure were ana-
lyzed by the method above and presented in Table 2.
We observed that the proportion of high mannose type 
glycan was nearly identical in SP cells (77.21 %) and MP 
cells (77.90  %). Signal of m/z 2067.9 was significantly 
higher (p  <  0.01, fold change >1.5) in SP cells. In addi-
tion, the proportion of hybrid type N-glycan was obvi-
ously decreased in SP cells as compared with MP cells 
(10.44 vs. 12.30 %). Most hybrid N-glycans were reduced 
in SP cells, 1460.8 was significantly decreased (p < 0.01, 
fold change <0.67) in SP cells. However, the percentage 
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Fig. 1 Separation of SP cells from the HO8910 pm cell line and verification of their stemness. a Detection of SP cells from high-grade serous ovarian 
cancer cells lines. Cells were stained with the dye Hoechst 33342 and analyzed by flow cytometry. The ratio of SP cells was highest in HO8910 pm 
cells. b The spheres that formed after 21 days of culturing in an ultra-low attachment plate were much larger of SP cells than MP cells. c More 
spheres formed of SP cells than MP cells. d The mRNA expression of Oct4 and Nanog was up-regulated in SP cells. e SP cells were arrested in G1 
stage
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of complex N-glycans ranging from m/z 1200 to m/z 
2400 was slightly increased in SP cells (12.35 vs. 9.79 %). 
Among complex N-glycans, core fucosylated N-glycans, 
catalyzed by fucosyltransferase-8 (FUT8), were also 
higher in SP cells (4.64 vs. 3.42 %), and m/z 1485.6 and 
m/z 1688.7 were also significantly higher (p < 0.01, fold 
change >1.5). These results correlated well with the lectin 
array results (Fig. 2). Moreover, real-time PCR was per-
formed to further verify that SP cells expressed a higher 
level of FUT8-encoding gene Fut8 at mRNA level.
SP cells exhibit higher signal intensity for ABA and VVA
Lectin array analysis indicated that SP cells expressed 
more tumor-associated antigens which strongly bound 
to the lectins ABA and VVA. Among all 45 lectins, ABA, 
which can recognize both T and sT antigens, exhibited 
the strongest intensity for SP cells. VVA, which can rec-
ognize Tn antigen, also displayed significantly higher 
intensity for SP cells. Hence, we performed lectin blots 
to compare recognition of ABA and VVA between SP 
and MP cells. SP cells exhibited higher intensity for 
Fig. 2 Lectin array analysis of SP cells and MP cells. a Relative intensities of 45 lectins in SP cells compared with MP cells for two experiments.  
b Fluorescence intensities of SP cells (up) and MP cells (down)
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Table 1 Variation of glycans determined by lectin microarray analysis of SP cells and MP cells
No. Lectin Preferred glycan structure (terminal epitope) SP1 ± SD MP1 ± SD SP1/MP1 SP2 ± SD MP2 ± SD SP2/MP2
1 LTL Fuc α1-3(Gal β1-4)GlcNAc (Lex), Fuc α1-2(Gal β1-4)
GlcNAc
0.40 ± 0.02 0.40 ± 0.02 1.00 0.42 ± 0.02 0.45 ± 0.02 0.95
2 PSA Fuc α1-6GlcNAc, α-D-Glc, α-D-Man 0.78 ± 0.01 0.79 ± 0.06 0.99 0.82 ± 0.04 0.88 ± 0.02 0.93
3 LCA Fuc α1-6GlcNAc, α-D-Glc, α-D-Man 0.91 ± 0.07 0.84 ± 0.06 1.08 0.89 ± 0.01 0.89 ± 0.03 0.99
4 UEA-I Fuc α1-2(Gal β1-4)GlcNAc 0.41 ± 0.02 0.53 ± 0.03 0.78** 0.60 ± 0.02 0.61 ± 0.01 0.99
5 AOL Fuc α1-6GlcNAc (core Fuc), Fuc α1-2(Gal β1-4)GlcNAc 0.93 ± 0.34 0.65 ± 0.04 1.43 0.58 ± 0.04 0.55 ± 0.04 1.05
6 AALª Fuc α1-6GlcNAc (core Fuc), Fuc α1-3(Gal β1-4)GlcNAc 
(Lex)
1.22 ± 0.09 1.07 ± 0.04 1.14* 0.95 ± 0.05 0.87 ± 0.01 1.10*
7 MALª Sia α2-3Gal β1-4GlcNAc 0.47 ± 0.02 0.60 ± 0.01 0.77*** 0.63 ± 0.02 0.70 ± 0.01 0.90**
8 SNA Sia α2-6Gal/GalNAc 0.82 ± 0.02 1.01 ± 0.05 0.81** 1.03 ± 0.03 0.90 ± 0.03 1.14**
9 SSA Sia α2-6Gal/GalNAc 0.75 ± 0.04 0.90 ± 0.06 0.84* 1.03 ± 0.01 0.92 ± 0.01 1.11***
10 TJA-I Sia α2-6Gal/GalNAc 1.65 ± 0.01 2.28 ± 0.08 0.73*** 1.66 ± 0.15 1.56 ± 0.06 1.06
11 PHA-L Tri/Tetra-antennary complex-type N-glycan 0.45 ± 0.03 0.45 ± 0.01 1.00 0.54 ± 0.01 0.59 ± 0.01 0.91**
12 ECA Gal β1-4GlcNAc 0.86 ± 0.04 0.93 ± 0.04 0.93 1.12 ± 0.04 1.18 ± 0.04 0.95
13 RCA120 Gal β1-4GlcNAc 1.60 ± 0.07 2.43 ± 0.20 0.66** 2.13 ± 0.08 2.25 ± 0.12 0.95
14 PHA-E Complex-type N-glycans with outer Gal and bisecting 
GlcNAc
0.75 ± 0.05 1.33 ± 0.06 0.57*** 1.01 ± 0.02 0.88 ± 0.05 1.15*
15 DSAª (GlcNAc β1-4)n, Gal β1-4GlcNAc, Tri/Tetra-antennary 
N-glycans
1.75 ± 0.03 2.21 ± 0.06 0.79*** 1.78 ± 0.04 2.04 ± 0.04 0.87**
16 GSL-II Agalactosylated tri/tetra antennary glycans, GlcNAc 0.48 ± 0.02 0.31 ± 0.00 1.52*** 0.44 ± 0.02 0.43 ± 0.01 1.04
17 NPA High Man, Man α1-6Man 1.52 ± 0.17 1.68 ± 0.03 0.90 1.41 ± 0.04 1.38 ± 0.07 1.02
18 ConA High Man, Man α1-6(Man α1-3)Man (inhibited by pres-
ence of bisecting GlcNAc)
2.29 ± 0.23 2.23 ± 0.16 1.03 1.68 ± 0.11 1.59 ± 0.09 1.06
19 GNA High Man, Man α1-3Man 0.98 ± 0.08 1.10 ± 0.01 0.89 1.02 ± 0.02 0.97 ± 0.03 1.05
20 HHL High Man, Man α1-3Man, Man α1-6Man 0.67 ± 0.04 0.58 ± 0.01 1.17* 0.75 ± 0.02 0.74 ± 0.03 1.01
21 ACG Sia α2-3Gal β1-4GlcNAc 1.36 ± 0.18 1.59 ± 0.09 0.85 1.38 ± 0.07 1.57 ± 0.05 0.88*
22 TxLC-I Man3 core, bi- and tri-antennary complex-type N-glycan, 
GalNAc
1.06 ± 0.04 0.80 ± 0.05 1.32** 0.97 ± 0.05 0.93 ± 0.04 1.04
23 BPL Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc 0.54 ± 0.05 0.53 ± 0.03 1.01 0.66 ± 0.02 0.63 ± 0.02 1.05
24 TJA-II Fuc α1-2Gal β1-4, GalNAcβ1-4 groups at their nonreduc-
ing terminals
0.92 ± 0.04 1.01 ± 0.02 0.90* 1.11 ± 0.06 1.12 ± 0.03 0.99
25 EEL Gal α1-3Gal β1-4GlcNAc, Fuc α1-2(Gal α1-3)Galβ1-
4GlcNAc
0.58 ± 0.04 0.33 ± 0.02 1.74** 0.51 ± 0.02 0.52 ± 0.01 0.98
26 ABAª Gal β1-3GalNAc (α-Thr/Ser (T)), GlcNAc, sialyl-T 2.16 ± 0.08 0.84 ± 0.06 2.58*** 0.89 ± 0.01 0.84 ± 0.01 1.06*
27 LELª (GlcNAc β1-4)n, (Gal β1-4GlcNAc)n (polyLacNAc) 2.39 ± 0.12 2.75 ± 0.16 0.87* 2.95 ± 0.08 3.16 ± 0.09 0.94*
28 STL (GlcNAc)n, (GlcNAc β1-4MurNAc)n (peptidoglycan 
backbone)
1.77 ± 0.13 2.19 ± 0.14 0.81* 2.21 ± 0.16 2.36 ± 0.09 0.94
29 UDA GlcNAc β1-4GlcNAc, Mixture of Man5 to Man9 1.65 ± 0.16 2.09 ± 0.32 0.79 1.62 ± 0.21 1.94 ± 0.26 0.84
30 PWM (GlcNAc α1-4)n 0.52 ± 0.04 0.58 ± 0.08 0.90 0.82 ± 0.00 0.84 ± 0.03 0.98
31 Jacalin Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn)) 1.51 ± 0.25 1.55 ± 0.15 0.97 1.64 ± 0.04 1.60 ± 0.09 1.02
32 PNAª Gal β1-3GalNAc (α-Thr/Ser (T)) 0.68 ± 0.09 0.36 ± 0.01 1.86** 0.49 ± 0.01 0.43 ± 0.01 1.14**
33 WFA Terminal GalNAc (e.g. GalNAcβ1-4GlcNAc), Galβ1-3(-6)
GalNAc
0.52 ± 0.05 0.51 ± 0.02 1.03 0.71 ± 0.08 0.66 ± 0.06 1.08
34 ACA Gal β1-3GalNAc (α-Thr/Ser (T)) 2.20 ± 0.15 1.16 ± 0.14 1.90*** 0.87 ± 0.07 0.97 ± 0.05 0.90
35 MPA Gal β1-3GalNAc (α-Thr/Ser (T)), GalNAc (α-Thr/Ser (Tn)) 0.81 ± 0.08 0.50 ± 0.02 1.61** 0.71 ± 0.04 0.66 ± 0.04 1.08
36 HPA α-Linked terminal GalNAc 0.89 ± 0.04 0.43 ± 0.05 2.08*** 0.45 ± 0.03 0.45 ± 0.02 1.01
37 VVAª α-linked terminal GalNAc (α-Thr/Ser (Tn), GalNAc α1-3Gal 0.55 ± 0.03 0.44 ± 0.02 1.24** 0.59 ± 0.03 0.43 ± 0.00 1.35***
38 DBA GalNAc α1-3GalNAc (Blood group A), GalNAc 
α1-3GalNAc
0.41 ± 0.04 0.34 ± 0.01 1.21* 0.46 ± 0.01 0.46 ± 0.01 1.00
39 SBA α or β-linked terminal GalNAc, GalNAc α1-3Gal 0.56 ± 0.06 0.51 ± 0.05 1.10 0.78 ± 0.04 0.66 ± 0.02 1.18**
40 Calsepaª High Man (Man2-6), N-glycans including bisecting 
GlcNAc
0.79 ± 0.05 0.66 ± 0.02 1.21* 0.80 ± 0.05 0.67 ± 0.02 1.20*
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both lectins. For ABA, intensity of glycoprotein from 
70–180 kDa was higher in SP cells. For VVA, glycopro-
tein from 50–80  kDa showed stronger intensity in SP 
cells (Fig. 5a). These differences were further verified by 
real-time PCR. C1GALT1 (core 1 synthase, glycoprotein-
N-acetylgalactosamine 3-beta-galactosyltransferase 1), 
which acts on Tn to form a T antigen, was increased in 
SP cells at mRNA level. ST3Gal1 (ST3 beta-galactoside 
alpha-2,3-sialyltransferase 1), which can modify T anti-
gens to form sT, was also enhanced in SP cells (Fig. 5b).
To investigate whether the SP cells continued to display 
enhanced binding for ABA and VVA during proliferation, 
a Significantly changed in two experiments; * p < 0.05; ** p < 0.01; *** p < 0.001
Table 1 continued
No. Lectin Preferred glycan structure (terminal epitope) SP1 ± SD MP1 ± SD SP1/MP1 SP2 ± SD MP2 ± SD SP2/MP2
41 PTL-I α-Linked terminal GalNAc 0.48 ± 0.03 0.53 ± 0.05 0.92 0.59 ± 0.04 0.50 ± 0.02 1.17*
42 MAH Sia α2-3Gal β1-3(Sia α2-6) GalNAc 0.37 ± 0.03 0.49 ± 0.04 0.76* 0.53 ± 0.02 0.50 ± 0.02 1.05
43 WGAª (GlcNAcβ1-4)n, NeuAc, multivalent Sia 1.32 ± 0.09 1.52 ± 0.07 0.87* 1.39 ± 0.02 1.48 ± 0.03 0.93**
44 GSL-IA4 α-GalNAc (α-Thr/Ser (Tn)) 0.53 ± 0.06 0.43 ± 0.03 1.22 0.70 ± 0.01 0.63 ± 0.02 1.11**
45 GSL-IB4ª α-Gal 0.75 ± 0.02 0.55 ± 0.03 1.35*** 0.69 ± 0.01 0.62 ± 0.02 1.11**
Fig. 3 MS spectra of SP cells and MP cells. a, b The spectra from m/z 1250 to m/z 2400 of SP cells (up) and MP (down). Int % of each peak means the 
relative ion intensity and stand for the ratio of each oligosaccharides’ intensity to the intensity of the highest oligosaccharides
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we detected the intensity of ABA and VVA for MP and 
SP sphere cells after 5  weeks’ culture. Both ABA and 
VVA continued to strongly bind to SP cells, indicating 
that these lectins might be potential markers of ovarian 
cancer SP cells (Fig. 5c, d).
Discussion
Glycosylation plays important roles in many physiologi-
cal and pathological processes as well as the identity and 
function of CSCs. However, the small population size 
of CSCs has hindered the characterization of glycans 
released from CSCs. Thus, we used lectin arrays to char-
acterize the entire glycome of CSCs, both N-glycans and 
O-glycans. Lectin array is time saving (1-day operation), 
requires small amount of cells (lower limit of 1000 cells). 
And it can analyze intact glycoproteins, which simplified 
sample preparation and made detection of sialic acid 
easy. We also used MS to characterize the structure of 
N-glycans and provide information about the composi-
tion of the N-glycome. Combination of these two meth-
ods provided more comprehensive information about 
glycans in ovarian CSCs. In this study, we didn’t conduct 
MS analysis of O-glycans, because it needs 106–107 cells 
at least for analysis [24], and it was difficult to enrich 
enough HO8910 pm SP cells. New methods or technolo-
gies are still needed to overcome these obstacles.
Our present study suggested that SP cells may overex-
press the tumor-associated antigens, T, Tn, and sT. The 
lectin arrays revealed enhanced intensity of VVA, SBA, 
and GSL-IA lectins in SP cells, which implied Tn anti-
gen overexpession in SP cells. Increased expression of 
C1GALT1 and signal intensity of ABA and PNA lectins in 
Fig. 4 Relative quantities of different classes of N-glycans in SP cells and MP cells. a Comparison of the relative quantities of each structure on SP 
cells and MP cell. The relative quantity of each structure was stand for the proportion of each structure relative intensity in total intensity of all 25 
structures. b Comparison of the different classes of glycans using a pie chart: the inner circle represents SP cells, and the outer circle represents MP 
cells. c The expression of Fut8 was analysed by quantitative real-time RT-PCR
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SP cells suggested upregulation of T antigen. Besides, T 
antigens were modified by ST3Gal1, which was enhanced 
in SP cells, to form sT antigen recognized by ABA lectin. 
Our lectin blot results also confirmed stronger intensity 
of ABA, VVA for SP cells. Furthermore, after 5  weeks’ 
culture without serum, the SP sphere cells still displayed 
higher intensity of ABA and VVA compared with MP 
cells, indicating that the expression of these antigens 
continued during CSC proliferation. To further verify 
whether these changes were only HO8910  pm cell line 
specific, we used another ovarian cancer cell line ES-2 
for SP cell sorting and validated that ES-2 SP cells also 
showed higher intensity of ABA and VVA than ES-2 MP 
cells (see Additional file 1).
In our MS analysis, glycans with terminal Glcs (glu-
cose), which are usually related to glycoprotein qual-
ity control [25, 26] and exhibit higher expression in 
cancer [27, 28], were expressed more abundantly in SP 
cells. Increased hybrid N-glycans were detected in MP 
cells, indicating that the immediate products of GlcNAc 
transferase I were not further modified by other Glc-
NAc transferases. Among more mature N-glycans, core 
fucosylation N-glycans were more abundant in SP cells, 
as verified by MS and lectin array. The mRNA transcript 
level of FUT8, which synthesises the core fucosylation, 
was also enhanced. Increased core fucose is closely asso-
ciated with many types of cancer. It showed an unfavour-
able clinical outcome and played as a functional regulator 
of non-small cell lung cancer [29, 30]. Loss of FUT8 also 
down-regulates several cellular signaling pathways to 
inhibit chemical-induced hepatocellular carcinoma [31].
The common available biomarkers of ovarian CSCs are 
ALDH, CD133+, CD24+ CD44+, CD44+ CD117+ and 
negative Hoechst 33342 stain. The use of a single marker 
has disadvantages because not all cancer cell lines or tis-
sues are positive for the marker and the cells enriched for 
Fig. 5 SP cellsexhibited higher intensity of ABA and VVA. a Lectin blots were used to detect the expression of the Tn (VVA, right), T and ST (ABA, left) 
antigens on SP cells and MP cells, β-actin was performed as control; b the mRNA expression levels of C1galt, which acts on Tn to form T antigen, 
and St3gal1, which forms ST antigen from T, were determined by real-time PCR. c, d The intensity of ABA and VVA for SP sphere cells after culturing 
for 5 weeks without serum was detected by flow cytometry and quantified
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a marker maybe not purified. In addition, ALDH, CD133, 
CD44, and CD177 are also expressed in normal stem 
cells. Thus, new biomarkers are still needed, and glycans 
may provide a breakthrough.
This study implied higher levels of Tn, T and sT anti-
gens in ovarian cancer SP cells. Tn, T and sT antigens are 
weakly expressed in normal tissues but overexpressed 
in most human carcinomas and are associated with 
poor prognosis [32–34]. A recent review by Karsten 
and Goletz [19] hypothesized that T antigen might be 
a potential biomarker of CSCs. Because this antigen is 
only expressed in onco-foetal stem cells and tumor cells, 
targeting T antigen should not harm normal adult stem 
cells. Lin et  al. also confirmed the co-expression of T 
antigen with the stem cell markers CD44 and CD133 in 
lung, breast and liver cancer [35].
Our results are similar to those of previous lectin stud-
ies of CSCs. In glioblastoma, lectins recognizing GalNAc 
and GlcNAc exhibit higher affinity for the surface of 
undifferentiated cells, suggesting that GalNAc and Glc-
NAc might be a novel biomarker to identify CSCs [19]. 
In the same study, the lectins PNA, GSL-I, SBA, and 
VVA also exhibited higher signals in CSCs. In pancre-
atic CSCs, Terao et al. observed enhanced ABA and VVA 
intensity of CSCs using the same lectin array [36]. In 
addition, liver CSCs isolated as CD133+CD13+cells also 
exhibited stronger intensities of SNA, SSA, ABA, PNA, 
and SBA [18].
Based on the results of the present study and previous 
reports, we hypothesize that tumor-associated glycan 
antigens may be novel potential CSC markers. Future 
studies should examine whether lectin ABA combined 
with available markers can isolate more malignant CSCs.
Conclusions
In conclusion, we conducted a systematic glycomic anal-
ysis of ovarian cancer SP cells using lectin arrays and MS. 
Our findings suggested that SP cells expressed increased 
core fucose, Tn, T and sT antigens. In addition, hybrid 
type, α2,3-linked sialic glycan, and multivalent sialyl-gly-
can were enhanced in MP cells. Aberrant glycan profiles 
may be related to some stemness properties of SP cells 
and may provide potential biomarkers for ovarian cancer 
CSCs (all lectins in the array: see Additional file 2).
Additional files
Additional file 1. SP cells sorted from ES-2 cells exhibited higher 
intensity of ABA and VVA. The intensity of ABA (left) and VVA (right) for SP 
sphere cells after culturing for 1weeks without serum was detected by 
flow cytometry.
Additional file 2. The category of representative lectins for glycan 
profiling.
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